Abstract

Background

The amount of plasma pentraxin 3 (PTX3) is gradually being considered as a novel biomarker in forecasting poor clinical outcomes in patients with coronary artery disease (CAD). However, very little is known about the connection between PTX3 and CAD. This dose–response meta-analysis was carried out to quantify the relationship between circulating PTX3 concentration and CAD prognosis.

Methods

A systematic literature search was conducted using PubMed, EuropePMC, ProQuest, EBSCOhost, SCOPUS, Cochrane Library, and Google Scholar up until April 2021. The primary outcome of this study consisted of mortality and major adverse cardiovascular events (MACEs).

Results

The current meta-analysis comprised 15 studies with a total of 11.365 participants. High circulating PTX3 concentrations were associated with a higher risk of composite poor outcomes as compared to low circulating PTX3 concentrations (OR: 1.36 [1.18, 1.54], p < 0.001; I² = 86.69%, P_{heterogeneity}<0.001), mortality (OR: 1.43 [1.15, 1.71], p < 0.001; I² = 87.58%, P_{heterogeneity}<0.001), and MACEs (OR: 1.28 [1.08, 1.48], p < 0.001; I² = 35.86%, P_{heterogeneity} = 0.08) in patients with CAD. Consistent results were obtained during meta-regression analyses and in all examined subgroups. The adjusted odds ratios (aORs) for composite poor outcomes increased by 32% per 1 ng/mL increment (OR: 1.32 [1.21, 1.43]) in line with the dose–response meta-analysis.

Conclusion

A significant positive dose-dependent association between circulating PTX3 concentration and the risk of poor outcomes in patients with CAD was found in this dose–response meta-analysis.

中文翻译：

---

Pentraxin 3 浓度与冠状动脉疾病患者的不良预后相关：系统评价和剂量反应荟萃分析

摘要

背景

血浆五聚蛋白 3 (PTX3) 的含量逐渐被认为是预测冠状动脉疾病 (CAD) 患者不良临床结果的新型生物标志物。然而，人们对 PTX3 和 CAD 之间的联系知之甚少。这项剂量反应荟萃分析旨在量化循环 PTX3 浓度与 CAD 预后之间的关系。

方法

使用 PubMed、EuropePMC、ProQuest、EBSCOhost、SCOPUS、Cochrane Library 和 Google Scholar 进行了系统的文献检索，直至 2021 年 4 月。这项研究的主要结果包括死亡率和主要不良心血管事件 (MACE)。

结果

目前的荟萃分析包括 15 项研究，共有 11.365 名参与者。与低循环 PTX3 浓度相比，高循环 PTX3 浓度与较高的复合不良结局风险相关（OR：1.36 [1.18, 1.54]，p  < 0.001；I ²  = 86.69%，P_异质性<0.001）、死亡率（OR : 1.43 [1.15, 1.71], p  < 0.001; I ²  = 87.58%, P_异质性<0.001) 和 MACE (OR: 1.28 [1.08, 1.48], p  < 0.001; I ²  = 35.86%, P_异质性 = 0.08) 在 CAD 患者中。在元回归分析和所有检查的亚组中获得了一致的结果。与剂量反应荟萃分析一致，复合不良结局的调整优势比 (aOR) 每增加 1 ng/mL 增加 32% (OR: 1.32 [1.21, 1.43])。

结论

在这项剂量反应荟萃分析中发现，循环 PTX3 浓度与 CAD 患者不良预后风险之间存在显着的正剂量依赖性关联。